Table 2 The number and frequency of patients on individual immunomodulatory agent
From: Patient Clinical Outcomes in Standalone Versus a Combined Ophthalmology-rheumatology Uveitis Clinic
Immunomodulatory therapy (IMT) | N (%) |
|---|---|
6 months prior | |
Not on IMT | 51 (68.9) |
Methotrexate | 17 (23.0) |
Adalimumab | 6 (8.1) |
Mycophenolate mofetil | 5 (6.8) |
Azathioprine | 3 (4.1) |
Infliximab | 3 (4.1) |
Tacrolimus | 2 (2.7) |
Cyclosporine | 1 (1.4) |
Sulfasalazine | 1 (1.4) |
Ocrelizumab | 1 (1.4) |
Etanercept | 1 (1.4) |
Initial combined visit | |
Not on IMT | 33 (44.6) |
Methotrexate | 26 (35.1) |
Adalimumab | 11 (14.9) |
Mycophenolate mofetil | 10 (13.5) |
Infliximab | 5 (6.8) |
Azathioprine | 4 (5.4) |
Tacrolimus | 1 (1.4) |
Cyclosporine | 1 (1.4) |
Sulfasalazine | 1 (1.4) |
Hydroxychloroquine | 1 (1.4) |
Dimethyl fumarate | 1 (1.4) |
Leflunomide | 1 (1.4) |
Secukinumab | 1 (1.4) |
Ocrelizumab | 1 (1.4) |
Etanercept | 1 (1.4) |
6 months after | |
Not on IMT | 34 (45.9) |
Methotrexate | 23 (31.1) |
Adalimumab | 11 (14.9) |
Mycophenolate mofetil | 9 (12.2) |
Azathioprine | 6 (8.1) |
Infliximab | 4 (5.4) |
Leflunomide | 2 (2.7) |
Sulfasalazine | 1 (1.4) |
Dimethyl fumarate | 1 (1.4) |
Tocilizumab | 1 (1.4) |
Golimumab | 1 (1.4) |